MorphoSys (MOR, Financial) is a German biotechnology company with proprietary technology to develop human antibodies for specific diseases. Over the quarter, the company signed two licensing deals (with GlaxoSmithKline PLC and Celgene Corp., not held by the fund) for its proprietary compounds, providing outside validation for its technology as well as upfront cash and future royalty payments.
From Invesco European Fund's second quarter commentary 2013.
From Invesco European Fund's second quarter commentary 2013.